Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

Forest Laboratories logo

Forest Laboratories

Status and phase

Terminated
Phase 3

Conditions

Diarrhea-predominant Irritable Bowel Syndrome

Treatments

Drug: PLACEBO
Drug: LACTEOL® 340 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01358708
MA-LA-IBS09-01

Details and patient eligibility

About

Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea. In this study, Lacteol® 340 mg will be evaluated as a potential therapy for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Full description

This study will include the following phases: Screening Phase, Run-In Phase, Double-Blind Treatment Phase and Open-Label Treatment Phase. Screening: Eligibility of subjects will be evaluated following informed consent signature. Screening procedures/evaluations (physical exam, concomitant medications, clinical laboratory tests) and confirmation of eligibility following Rome III Diagnostic questionnaire will be performed. Run-In: Subjects will enter a 2-week Run-In Phase during which IBS Symptoms and Stool Characteristics will be recorded. At the end of the Run-In Phase, data collected over the last week will be reviewed. Upon confirmation of IBS-D severity status, subjects may be randomized. Double-Blind Treatment: Subjects will take study medication (either LACTEOL® 340 mg or Placebo) for 28 days. During this time, IBS Symptoms and Stool Characteristics and global assessment of relief will be recorded, and clinical laboratory tests will be performed. HAD score will be assessed at the end of the double blind treatment. Open-Label Treatment: All study completers will be eligible for a second 28 day Open-Label Treatment in the event that IBS-D symptoms remain or recur within the month following the end of Double-Blind Treatment. Subjects will take the study medication (LACTEOL® 340 mg) for 28 days. During this time, IBS Symptoms and Stool Characteristics and global assessment of relief will be recorded, and clinical laboratory tests will be performed.

Enrollment

26 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • IBS-D diagnosis using the Rome III questionnaire
  • IBS Symptoms Severity Scale (IBS-SSS) score ranging between 100 and 400
  • Bristol Stool Form Scale score exceeding two (> 2) but less than seven (< 7)
  • Stable diet
  • Mental and legal ability to sign informed consent

Exclusion criteria

  • Diagnosis of Inflammatory Bowel Disease (IBD)
  • Chronic use of systemic steroids
  • Diagnosis of autoimmune Diseases or Disorders
  • Invasive abdominal surgery
  • Use of antibiotics prior to screening
  • Allergy to active substance or any other ingredient in LACTEOL® 340 mg
  • Congenital galactosemia, glucose, fructose and/or galactose malabsorption syndrome, lactase deficiency or lactose intolerance
  • Diagnosis of exocrine pancreatic insufficiency
  • Use of any experimental drug within the 30 days prior to screening

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

26 participants in 2 patient groups, including a placebo group

LACTEOL® 340 mg
Experimental group
Treatment:
Drug: LACTEOL® 340 mg
PLACEBO
Placebo Comparator group
Treatment:
Drug: PLACEBO

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems